Valérie Brunner

Randomized, double-blind, placebo-controlled study of F17464, a preferential D3 antagonist, in the treatment of acute exacerbation of schizophrenia

István Bitter, Jeffrey A. Lieberman, Florence Gaudoux et al. · Neuropsychopharmacology · 2019 · 34 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

Smart e-Patch for drugs monitoring in schizophrenia

Tuğba Kiliç, Valérie Brunner, Laurent Audoly et al. · 2016 · 26 citations

Engineering, Bioengineering, Biomedical Engineering +17

Propranolol pharmacokinetics in infants treated for Infantile Hemangiomas requiring systemic therapy: Modeling and dosing regimen recommendations

Laurence Del Frari, C. Léauté‐Labrèze, Laurent Guibaud et al. · Pharmacology Research & Perspectives · 2018 · 24 citations · Full text

Pharmacy, Pediatrics, Pharmacology +17

A pharmacogically guided phase I study of carboplatin in combination with methotrexate and vinblastine in advanced urothelial cancer

Étienne Chatelut, Christine Chevreau, Valérie Brunner et al. · Cancer Chemotherapy and Pharmacology · 1995 · 17 citations

Medicine, Oncology, Pharmacology +11

Binding of the D3-preferring antipsychotic candidate F17464 to dopamine D3 and D2 receptors: a PET study in healthy subjects with [11C]-(+)-PHNO

Mark Slifstein, Anissa Abi‐Dargham, Ragy R. Girgis et al. · Psychopharmacology · 2019 · 16 citations

Medicine, Neuroscience, Pharmacology +15